BACKGROUND: Propofol infusion syndrome (PRIS) is a potentially lethal consequence of long-term propofol administration. Children are vulnerable and cardiac involvement is often prominent and associated with mortality. We aimed to determine the mechanism of propofol toxicity in newborn mice, hypothesizing that propofol would induce discrete defects within immature cardiac mitochondria.

METHODS: Newborn murine cardiac mitochondria were exposed to propofol or intralipid in vitro. Non-exposed mitochondria served as controls. Mitochondrial respiration and membrane potential (ΔΨ) were measured and respiratory chain complex kinetics were determined.

RESULTS: Propofol and intralipid exerted biological activity in isolated mitochondria. Although intralipid effects were a potential confounder, we found that propofol induced a dose-dependent increase in proton leak and caused a defect in substrate oxidation at coenzyme Q (CoQ). These impairments prevented propofol-exposed cardiomyocyte mitochondria from generating an adequate ΔΨ. The addition of the quinone analog, CoQ0, blocked propofol-induced leak and increased Complex II+III activity.

CONCLUSIONS: Propofol uncoupled immature cardiomyocyte mitochondria by inducing excessive CoQ-sensitive leak and interfered with electron transport at CoQ. The findings provide new insight into the mechanisms of propofol toxicity in the developing heart and may help explain why children are vulnerable to developing PRIS.

Pediatric Research (2022) 92:1341–1349; https://doi.org/10.1038/s41390-022-01985-1

IMPACT:
- Propofol uncouples immature cardiomyocyte mitochondria by inducing excessive coenzyme Q (CoQ)-sensitive proton leak.
- Propofol also interferes with electron transport at the level of CoQ.
- These defects provide new insight into propofol toxicity in the developing heart.

INTRODUCTION
Propofol (2,6-diisopropylphenol) is the most common intravenous sedative–hypnotic used for general anesthesia.1–3 Because of its desirable pharmacokinetic properties, propofol is also widely utilized for procedural sedation in ambulatory settings and for non-procedural sedation of the critically ill.2 Propofol infusion syndrome (PRIS) is a potentially fatal adverse consequence that manifests with metabolic acidosis, arrhythmias, profound cardiac failure, rhabdomyolysis, hyperkalemia, hepatomegaly, hyperlipidemia, renal failure, fever, and lactatemia.1,2,4 There is a dose-dependent nature of the toxicity and most cases occurred in patients who were administered propofol for >48 h at doses exceeding 4 mg/kg/h.4

PRIS was first described in the 1990s in children who were sedated with propofol via continuous infusion in the intensive care unit (ICU).1–5 Virtually all developed bradyarrhythmias, cardiac conduction abnormalities, and profound myocardial failure. Importantly, cardiac involvement was associated with mortality in most of these pediatric cases.6–7 The syndrome was also recently described in a relatively healthy newborn following a single bolus of propofol for induction of anesthesia in which bradycardia and hemodynamic instability were early and prominent features.8 Because PRIS can be lethal, the US Food and Drug Administration has warned against propofol use for sedation of pediatric patients in the ICU setting.9

The exact pathophysiology of PRIS has yet to be clearly defined. Evidence, however, exists to suggest that propofol interacts with various components of the electron transport chain (ETC).1,2 For example, propofol inhibits Complexes I and IV at different concentrations and potentially interferes with the redox activity of coenzyme Q (CoQ).4,10–12 In addition, propofol uncouples non-phosphorylating mitochondria by enhancing proton leak.10 Furthermore, it has been suggested that PRIS might result from an acquired fatty acid oxidation defect due to carnitine palmitoyltransferase I inhibition.13

Despite the fact that children are vulnerable to developing PRIS and that young age may be a risk factor, little information is available regarding the mechanism of propofol-mediated toxicity during development.6 In addition, the toxicological effects of propofol in the context of PRIS have never been assessed in immature mitochondria. PRIS is considered to be pediatric in nature when it occurs in children under 16 years of age.1
Although this is a wide age range, the majority of pediatric cases have occurred in infants and younger children. Thus, we aimed to determine the mechanism of propofol toxicity in newborn mice, modeling for exposure during human infancy. We focused on cardiomyocyte mitochondria and the developing heart given the high incidence of cardiac involvement in children who develop PRIS and the association between acquired cardiovascular disturbances and propofol-related mortality. We hypothesized that propofol would induce discrete defects within immature cardiac mitochondria. Using an in vitro approach, we found that propofol uncoupled immature cardiomyocyte mitochondria by inducing excessive CoQ-sensitive proton leak and interfered with electron transport at CoQ. Importantly, these defects were targetable, providing new insight into the mechanism of propofol toxicity in the developing heart.

MATERIALS AND METHODS

Animals

Care was in accordance with NIH and CUMC IACUC guidelines. Six–8-week-old C57BL/6N breeding pairs were acquired (Charles River, Wilmington, MA) to yield male pups. P10 modeled a timepoint in human infancy.

Mitochondrial isolation

Cardiac ventricles were harvested, homogenized in ice-cold buffer (225 mM mannitol, 75 mM sucrose, 1 mM EGTA, 5 mM HEPES-KOH (pH 7.2) and 1 mg/mL of fatty-acid-free bovine serum albumin (BSA)), and centrifuged (1100 × g) for 5 min at 4 °C. The supernatant was centrifuged (18,500 × g) for 10 min at 4 °C using 15 % Percoll gradient. Pellet was suspended in buffer and centrifuged (10,000 × g) for 10 min at 4 °C. Pellet was resuspended and protein concentration was determined.

In vitro exposure

Mitochondria were exposed to propofol (Diprivan, Fresenius Kabi, Lake Zurich, Illinois) in vitro (50, 100, 200, or 400 µM). Concentrations were chosen based on the therapeutic range (5–30 µM in plasma and 60–90 µM in tissue). Although propofol levels reach 400 µM in the heart following a single bolus, concentrations chosen for in vitro exposure modeled supratherapeutic propofol exposures, generally within the toxic range. Injectable emulsion permitted assessment of the clinical formulation, recognizing it is unknown if emulsion reaches mitochondria without a change in composition following injection. In vitro intralipid (10%, equal volume as 400 µM propofol, Sigma-Aldrich, St. Louis, MO) exposure controlled for propofol solvent. A separate cohort was assessed in the absence of propofol or lipid to serve as non-exposed controls.

Mitochondrial oxygen consumption

Mitochondria (50 µg) were assessed in 0.5–ML respiration buffer (200 mM sucrose, 25 mM KCl, 2 mM K$_2$HPO$_4$, 5 mM HEPES-KOH (pH 7.2), 5 mM MgCl$_2$, 0.2 mg/mL BSA) with a Clark-type electrode (Oxytherm, Hansatech, UK) using Complex I-dependent (10 mM glutamate, 5 mM malate) or Complex II-dependent (10 mM succinate with 5 µM rotenone) substrates at 32 °C. State 3 was initiated with ADP (200 µM). State 4 was induced with oligomycin (2.5 µg/mL) and uncoupled state 3 respiration was initiated using dinitrophenol (DNP; 70 µM).

Modular kinetics

Proton leak, substrate oxidation, and ATP turnover were measured in the presence of 400 µM propofol, equal volume 10% intralipid, or in non-exposed mitochondria. Oxygen consumption and mitochondrial membrane potential (ΔΨ) were measured in mitochondria (0.1 mg) in 1-ML respiration buffer containing 80 ng/mL nigericin (to collapse ΔΨ) and 5 µM rotenone at 37 °C. ΔΨ was quantified using an electrode selective for tetraphenylphosphonium (World Precision Instruments, Sarasota, FL). Respiration was initiated using 5 mM succinate. For proton leak, respiration was induced with oligomycin (2.5 µg/mL) and titrated with up to 2 mM malonate. For substrate oxidation, state 4 was induced with oligomycin (2.5 µg/mL) and titrated with DNP (up to 100 µM). For ATP turnover, state 3 was initiated with an ADP-regenerating system (100 µM ATP, 20 mM glucose, and 10 units/mL hexokinase [baker’s yeast, Sigma-Aldrich]) and titrated with up to 200 µM malonate.

In separate experiments, oligomycin (2.5 µg/mL) was added following ADP (200 µM) to test for reverse activity of the ATP synthase. To determine leak source during state 4, cyclosporine A (CsA, 1 µM), carboxyatractyloside (CAT, 1 µM), and guanosine diphosphate (GDP, 0.75 mM) were added to inhibit the mitochondrial permeability transition pore (mPTP), the adenine nucleotide translocase (ANT), and uncoupling proteins (UCPs), respectively.

Steady-state ETC enzyme activity

Citrate synthase activity was determined (Sigma-Aldrich CS0720) in isolated mitochondria using spectrophotometry. Inhibitor-sensitive respiratory chain complex activities were measured in 1-ML volume spectrophoto metrically in the presence of 400 µM propofol or equal volume 10% intralipid or in non-exposed mitochondria and normalized to citrate synthase activity. Rotenone-sensitive Complex I-specific activity was measured in mitochondria (40 µg) with 4.8 mM M – 1 cm – 1 as the extinction coefficient of NADH at 340 nm using a reference wavelength of 380 nm. 2-Thenoyltrifluoroacetone-sensitive Complex II activity was determined in mitochondria (40 µg) using 19.1 mM M – 1 cm – 1 as the extinction coefficient of 2,6-dichlorophenolindophenol at 600 nm. For Complexes III and IV, inhibitor-sensitive first-order rate constants were calculated in mitochondria (4 and 2 µg, respectively) using 18.5 mM M – 1 cm – 1 as the extinction coefficient of cytochrome c at 550 nm. Oligomycin-sensitive Complex V specific activity was measured in mitochondria (40 µg) with 6.2 mM M – 1 cm – 1 as the extinction coefficient of NADH at 340 nm. Rotenone-sensitive Complex I–III linked activity and antimycin A-sensitive Complex II–III linked activity were determined separately in mitochondria (40 µg) with 18.5 mM M – 1 cm – 1 as the extinction coefficient of cytochrome c at 550 nm.

Effect of exogenous quinones

Effect of CoQ$_0$ (2,3-dimethoxy-5-methyl-2,6-dichlorophenolindophenol, 100 µM, Sigma-Aldrich) on steady-state Complex II–III activity was determined in propofol-, intralipidal-, and non-exposed mitochondria. Menaquinone-4 (100 µM, Sigma-Aldrich) served as control quinone given the lack of electron carrier activity. Separately, CoQ$_0$ and menaquinone-4 (50 µM) were added to respiring mitochondria to determine the effect on oligomycin-induced leak respiration.

Statistical analysis

Data were assessed for normality by examining histograms and box plots. Statistical analysis was performed using GraphPad Prism 8 (GraphPad Software, La Jolla, CA). Data are presented as means ± SD (unless otherwise indicated). The sample number for each experiment is indicated in the figure legends. Differences between and within exposed cohorts were assessed using a one-way analysis of variance with Tukey’s post hoc test. Two-tailed, unpaired Student’s t test compared differences in modular kinetics respiration rates or ΔΨ between groups. Significance set at P < 0.05.

RESULTS

Toxic concentrations of propofol alter oxygen consumption

To determine in vitro concentration-dependent effects of propofol, we first measured respiration using a Clark-type electrode in mitochondria harvested from newborn mice on postnatal day 10 and young adults at 8 weeks of age. In immature mitochondria, propofol induced dose-dependent increases in state 2 and state 4 respiration for Complex I-dependent substrates and significantly decreased dinitrophenol (DNP)-induced state 3 at the highest concentration (Fig. 1b). For Complex II-dependent substrate, propofol induced dose-dependent increases in state 2, state 4, and oligomycin-induced state 4 respiration (Fig. 1c). There was no effect of propofol on Complex II-dependent state 3 (Fig. 1c). Thus, propofol uncoupled respiration in immature mitochondria by inducing proton leak regardless of substrate and inhibited Complex I-dependent respiration at the highest concentration. This was supported by significant decreases in respiratory control and DNP-to-oligomycin ratios (Fig. 1b, c).

In mature mitochondria, propofol inhibited respiration regardless of substrate, as evidenced by a significant decrease in state 3 or DNP-induced state 3 respiration, and induced leak only with
Complex II-dependent substrate (Supplemental Figure). When comparing the change in oxygen consumption from control between immature and mature mitochondria during exposure to the highest concentration of propofol, the directionality of change was equivalent between groups for each state of respiration (Fig. 1d, e). However, the percent change in state 3 and DNP-induced state 3 respiration was significantly greater in 8-week-old cardiomyocyte mitochondria for Complex I-dependent substrates (Supplemental Figure). When comparing the change in oxygen consumption from control with mitochondrial membrane potential (ΔΨ) over a range of potentials to dynamically assess the interconnected processes that relate to the proton motive force. Thus, the approach permits precise interpretation of changes in proton leak, substrate oxidation, and ATP turnover.

With the proton leak module, propofol and intralipid shifted the conductance curves to the left of controls such that the rates of oxygen consumption at the highest common ΔΨ were significantly increased in propofol- and lipid-exposed mitochondria (Fig. 2a). Therefore, propofol and intralipid induced significant proton leak. With substrate oxidation, both propofol and intralipid
flattened the curve (Fig. 2b). However, lipid significantly increased the oxygen consumption rate at the highest common ΔΨ relative to controls, while propofol had no significant effect (Fig. 2b). The substrate oxidation curve was left-shifted in propofol-exposed mitochondria with a significantly decreased ΔΨ compared to intralipid (Fig. 2b). Thus, intralipid induced an increase in substrate oxidation that was not observed in propofol-exposed mitochondria. Taken together, the data indicated that both propofol and intralipid increased proton conductance in immature mitochondria. However, intralipid-exposed mitochondria compensated for excessive proton leak by increasing substrate oxidation to generate an adequate ΔΨ, while propofol-exposed mitochondria failed to do so.

With regard to ATP turnover, propofol shifted the curve to the left of control and intralipid-exposed mitochondria and significantly increased mitochondrial respiration at the highest common ΔΨ (Fig. 2c). Thus, propofol increased ATP synthesis, export, and turnover. As with substrate oxidation, ΔΨ was significantly lower in propofol-exposed mitochondria relative to intralipid-exposed mitochondria (Fig. 2c). We hypothesized that the increase in ATP turnover in propofol-exposed mitochondria was due, in part, to reverse activity of the ATP synthase, consuming ATP to pump protons in the setting of compromised ΔΨ.27 To test this, we measured the hydrolytic activity of Complex V via spectrophotometry and
determined the effect of the ATPase inhibitor, oligomycin, on ΔΨ in during in vitro exposure to propofol. We found significantly increased steady-state hydrolytic activity of Complex V in propofol-exposed mitochondria and ΔΨ steadily declined following the addition of oligomycin (Fig. 3). Thus, propofol-induced ATP synthase reverse activity. However, increased ATP turnover was futile given the inability to defend and maintain the ΔΨ during propofol exposure. The increase in hydrolytic activity of Complex V in intralipid-exposed mitochondria was consistent with the known stimulatory effects of fatty acids on the rate of ATP hydolysis (Fig. 3a).28 Such stimulation is thought to be related to lipid-induced increases in membrane conductance.28

Sources of proton leak
Proton leak is largely mediated by the adenine nucleotide translocase (ANT), uncoupling proteins (UCPs), and the mitochondrial permeability transition pore (mPTP).21,22 Therefore, we utilized specific inhibitors to delineate the known sources of leak during state 4 respiration. Both propofol and intralipid increased proton leak, evidenced by elevated oligomycin-induced state 4 respiration rates (Fig. 4). ΔΨ was lower in the presence of propofol, suggesting a defect in generating an adequate ΔΨ (Fig. 4). In controls, the ANT inhibitor, carboxyatractyloside (cAT), and the UCP inhibitor, guanosine diphosphate (GDP), decreased respiration and stabilized ΔΨ (Fig. 4). Thus, the ANT and UCPs were the predominant sources of physiological leak in controls. In intralipid-exposed mitochondria, of the inhibitors utilized, the greatest effect was seen with GDP (Fig. 4). This indicated that intralipid-induced proton leak was mediated largely via UCPs. It should be noted that persistent leak was evident following the addition of GDP, indicating the existence of other unknown and untested leak sources. CsA, cAT, and GDP each caused a decline in respiration in propofol-exposed mitochondria, suggesting the mPTP, ANT, and UCPs as sources of leak (Fig. 4). However, the persistent fall in ΔΨ without stabilization, especially following the noticeable upward deflection in ΔΨ (indicating closure of leak channel), suggested an unidentified source of propofol-induced pathological leak (Fig. 4).

Propofol interferes with electron transport at the level of CoQ
We next determined the in vitro effects of exposure on the steady-state kinetic activity of the ETC complexes to identify where propofol interfered with substrate oxidation. Propofol and intralipid profoundly inhibited Complex I (Fig. 5). Yet, intralipid significantly increased Complex II activity and markedly enhanced Complex I+III and Complex II+III linked activities (Fig. 5). The combined effect of intralipid on Complex I+III and II+III linked activities indicated stimulation of electron flux at CoQ (especially in the context of Complex I inhibition). Although the effects of propofol on Complex I+III and II+III diverged relative to controls, the linked activities were significantly lower than intralipid values (Fig. 5). Thus, propofol interfered with electron transport at CoQ.

A CoQ analog increases electron transport and blocks proton leak in propofol-exposed mitochondria
We next assessed the effect of the ubiquinone analog, CoQ0 (2,3-Dimethoxy-5-methyl-p-benzoquinone), on steady-state Complex II+III activity during in vitro exposure. We utilized this specific analog because it lacks a side chain, permitting rapid diffusion across the mitochondrial outer membrane.29 Menaquinone-4 (MQ) served as a control quinone given that it lacks electron carrier activity.25 MQ had no significant effect on Complex II+III activity in any group (Fig. 6a). In contrast, CoQ0 significantly increased Complex II+III activity within each exposure cohort in all groups compared to the effect of MQ, lack of added quinone, or both, indicating a CoQ-mediated increase in electron transport (Fig. 5a). Of note, CoQ0-treated propofol-exposed
these nuances, the limitations of utilizing the lipid solvent as a control group. Despite in vitro effect of CoQ0 on propofol-induced leak. Propofol induced exogenous CoQ can partially abrogate this effect.

Interrupts CoQ-dependent electron transfer and indicate that excess (Fig.6b). Although this appeared to differ from results depicted in Fig. 3b, ΔΨ stabilization occurred at a relatively low level after a longer period of observation. This likely reflected the effects of excessive proton leak and limited substrate oxidation (not complete inhibition). Thus, we anticipated the plateau of ΔΨ without a complete collapse. In contrast, CoQ0 immediately decreased oligomycin-induced state 4 respiration and induced a gradual and steady rise in ΔΨ (Fig. 6c). Thus, CoQ0 inhibited proton leak during in vitro propofol exposure. Taken together, the data suggest that propofol causes a pathological leak, in part, via a CoQ-sensitive leak channel and that CoQ0 can both increase electron flux and block excessive proton leak in propofol-exposed mitochondria.

**DISCUSSION**

Although the exact pathophysiology of PRIS remains unknown, there is general consensus that an acquired defect in mitochondrial function underlies this rare but potentially lethal process. Mounting evidence suggests that propofol inhibits and interferes with multiple enzymes and components within the ETC and disrupts fatty acid oxidation. However, the studies that provided such mechanistic insight focused largely on adult animals, evaluating only mature mitochondria from fully developed tissues and organs. Therefore, in this work, we assessed the toxicological effects of propofol in immature mitochondria given that children are vulnerable to developing PRIS and young age is a risk factor. We specifically studied cardiomyocyte mitochondria because of the high incidence of cardiac involvement in children who develop PRIS and the association between acquired cardiovascular disturbances and propofol-related mortality.

We found that toxic concentrations of propofol uncoupled immature cardiomyocyte mitochondria by inducing a dose-dependent increase in proton leak. We identified the ANT, UCPs, and the mPTP as sources of leak during propofol exposure and elucidated the important role of a CoQ-sensitive leak channel. Further in-depth analysis revealed that propofol also interfered
with electron transport at the level of CoQ, resulting in a relative defect in substrate oxidation. The combination of excessive proton leak and limited capacity to oxidize substrate prevented propofol-exposed cardiomyocyte mitochondria from generating an adequate ΔΨ. This impairment was profound enough to render reverse ATP synthase activity futile in an attempt to maintain and defend the ΔΨ.

Our results are consistent with findings from a previous investigation of mature mitochondria that found propofol to uncouple non-phosphorylating rat liver mitochondria from generating an adequate ΔΨ. However, no prior study evaluated the effect of propofol on both mature and immature mitochondria. Although we focused mostly on developing mitochondria in this work, we found propofol to affect actively respiring in newborn and young adult mitochondria differently. Further investigation will certainly be necessary to determine whether there are, indeed, age-dependent differences in response to propofol. Despite the unknowns, however, our findings provide some insight into why the young may be vulnerable to developing PRIS.

**Fig. 6** Effect of coenzyme Q₀ on electron transfer and proton leak. a Linked Complex I-II-III kinetic activity was measured in non-exposed controls and in mitochondria exposed to propofol (400 µM) or intralipid. Effect of CoQ₀ was compared with the effects of menaquinone-4 (MQ) and no added quinone (n = 4–7 per group). Values are expressed as means ± SD. p values were calculated by one-way ANOVA. *p < 0.05 vs. intralipid-exposed MQ-added cohort, control, and propofol-exposed CoQ₀-added cohorts, †p < 0.001 vs. control within quinone treatment group, ‡p < 0.001 vs. no added quinone, MQ within exposure cohort. b, c Oligomycin-induced state 4 respiration was initiated using succinate in the presence of propofol (400 µM). Representative tracings of oxygen consumption (above) with simultaneous ΔΨ measurement (below) are depicted (from 3 biological replicates in each group). Numbers indicate oxygen consumption rates (nmol/mL/min/mg mitochondrial protein). MQ or CoQ₀ were added to assess for the effect on leak.
developing heart.30 Closure of the mPTP induces a switch from anaerobic glycolysis to oxidative phosphorylation in developing cardiomyocytes, establishing the ΔΨ and triggering cellular differentiation.30–32 Cardiac mitochondria undergo maturation within the first few weeks of life, yet, the probability of mPTP opening remains high in the postnatal period, rendering the neonatal heart vulnerable to injury.30 Although the exact factors involved in regulating the mPTP during development are unknown, molecules, such as ubiquinone, serve as modulators.53 Biosynthesis of CoQ10 is low in infancy and increases in young adulthood.94 Thus, low CoQ levels in the context of a propofol-CoQ interaction could explain why the mPTP opens to enhance proton leak in the developing heart. This notion will need to be tested in future work.54

In addition to the mPTP, we identified a CoQ-sensitized leak channel as an important source of pathological proton leak in propofol-exposed mitochondria. Although we have yet to determine the exact proteinaceous identity of this specific channel, the CoQ-sensitive leak channel caused excessive proton conductance and compromised ΔΨ during propofol exposure. Evidence for this important role was found in the ability of the quinone analog, CoQ0, to block propofol-induced leak on its own and cause a gradual and steady rise in ΔΨ. Such an increase in ΔΨ only occurred with CoQ0 and was not observed with any other leak channel inhibitor. This indicated that CoQ0 inhibited the pathological proton leak, abrogated the defect in substrate oxidation, or both.

Newborn cardiomyocytes utilize lactate and glucose as metabolic substrates but undergo a switch to fatty acids in the postnatal period.18 Here we found that intralipid-stimulated mitochondrial respiration, increased substrate oxidation, and enhanced electron flux at the level of CoQ. This increase in substrate utilization permitted intralipid-exposed mitochondria to compensate for the fatty acid-mediated increase in proton leak in order to generate an adequate ΔΨ. Such biological activity, however, could confound interpretation of the effects of propofol and limits the utility of intralipid as a control vehicle. Intralipid contains soybean oil (a refined mixture of long-chain fatty acids, such as linoleic acid and oleic acid) and glycerol. Thus, it is likely that intralipid activated the fatty acid β-oxidation pathway to reduce CoQ directly via electron transfer flavoprotein:ubiquinone oxidoreductase or enhance electron flux through CoQ via glycerol-3-phosphate dehydrogenase-dependent respiration.7,33,35 Although the propofol emulsion contains the same formulation of soybean oil and glycerol as intralipid, exposure to propofol caused a relative impairment in substrate oxidation and modulated electron flow through CoQ. In the setting of excessive proton leak, this limitation in the ability to oxidize substrate prevented propofol-exposed mitochondria from generating an adequate ΔΨ. The propofol-induced defect likely involved modulation of one or more of the enzymes within the fatty oxidation pathway, the glycerol-3-phosphate dehydrogenase pathway, or both. Alternatively, the effect on electron flux through CoQ could have involved a direct interaction between propofol and ubiquinone itself. Importantly, exogenous CoQ0 enhanced quinone-dependent electron transfer during propofol exposure to partially abrogate the defect.

The dual effects of CoQ0 on proton leak and electron flux in propofol-exposed mitochondria are interesting and intriguing. In addition to providing experimental insight, the biological effects establish a foundation for us to develop quinone analogs as novel therapeutics to treat or prevent propofol toxicity in the developing heart. Importantly, our findings with CoQ0 support prior work demonstrating that CoQ10 prevented propofol-induced cytotoxicity in human induced pluripotent stem cell-derived cardiomyocytes and partially protected T67 and HELA cells.39,40 Thus, future work will focus on targeting propofol-mediated toxicity in the developing heart with CoQ0 and related compounds. We plan to extend our investigation using isolated perfused heart preparation and in vivo modeling. Ultimately, we hope to be able to prevent the life-threatening toxicity of propofol in infants and children.
30. Lingan, J., Alanzalon, R. E. & Porter, G. A. Jr. Preventing permeability transition pore opening increases mitochondrial maturation, myocyte differentiation and cardiac function in the neonatal mouse heart. *Pediatr. Res.* 81, 932–941 (2017).

31. Pérez, M. J. & Quintanilla, R. A. Development or disease: duality of the mitochondrial permeability transition pore. *Dev. Biol.* 426, 1–7 (2017).

32. Hrom, J. R. et al. The permeability transition pore controls cardiac mitochondrial maturation and myocyte differentiation. *Dev. Cell* 21, 469–478 (2011).

33. Walter, L. et al. Three classes of ubiquinone analogs regulate the mitochondrial permeability transition pore through a common site. *J. Biol. Chem.* 275, 29521–29527 (2000).

34. Zhang, Y., Appelkvist, E. L., Kristensson, K. & Dallner, G. The lipid compositions of different regions of rat brain during development and aging. *Neurobiol. Aging* 17, 869–875 (1996).

35. Tan, C. M. J. & Lewandowski, A. J. The transitional heart: from early embryonic and fetal development to neonatal life. *Fetal Diagn. Ther.* 47, 373–386 (2020).

36. Onay-Besikci, A. Regulation of cardiac energy metabolism in newborn. *Mol. Cell. Biochem.* 287, 1–11 (2006).

37. Watmough, N. J. & Freeman, F. E. The electron transfer flavoprotein: ubiquinone oxidoreductases. *Biochim. Biophys. Acta* 1797, 1910–1916 (2010).

38. Mráček, T., Dráhota, Z. & Houšťek, J. The function and the role of the mitochondrial glycerol-3-phosphate dehydrogenase in mammalian tissues. *Biochim. Biophys. Acta* 1827, 401–410 (2013).

39. Kido, K., Ito, H., Yamamoto, Y., Makita, K. & Uchida, T. Cytotoxicity of propofol in human induced pluripotent stem cell-derived cardiomyocytes. *J. Anesth.* 32, 120–131 (2018).

40. Bergamini, C. et al. Role of mitochondrial complex I and protective effect of CoQ10 supplementation in propofol induced cytotoxicity. *J. Bioenerg. Biomembr.* 48, 413–423 (2016).

**AUTHOR CONTRIBUTIONS**

Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data: M.B.B., S.D.B., A.W., K.K.G., R.J.L. Drafting the article or revising it critically for important intellectual content: M.B.B., S.D.B., R.J.L. Final approval of the version to be published: M.B.B., S.D.B., A.W., K.K.G., R.J.L.

**FUNDING**

This work was supported by NIH/NINDS R01NS112706 (to R.J.L.).

**COMPETING INTERESTS**

The authors declare no competing interests.

**ADDITIONAL INFORMATION**

**Supplementary information** The online version contains supplementary material available at https://doi.org/10.1038/s41390-022-01985-1.

**Correspondence** and requests for materials should be addressed to Richard J. Levy.

**Reprints and permission information** is available at http://www.nature.com/reprints

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022